- PA5-34401 - Invitrogen Antibodies BMP15 antibody

Yin Z, Sun JT, Cui HD, Jiang CQ, Zhang YT, Lee S, Liu ZH, Jin JX
Antioxidants (Basel, Switzerland) 2021 Oct 12;10(10)

Lee SH
International journal of molecular sciences 2021 Jan 8;22(2)

Kim EH, Ridlo MR, Lee BC, Kim GA
Antioxidants (Basel, Switzerland) 2020 Nov 3;9(11)

Kim EH, Taweechaipaisankul A, Ridlo MR, Kim GA, Lee BC
Aging 2020 Nov 16;12(23):23808-23821

Jin JX, Lee S, Setyawan EMN, Taweechaipaisankul A, Kim GA, Han HJ, Ahn C, Lee BC
Journal of cellular physiology 2018 Sep;233(9):6984-6995

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of 3T3 cell lysate using a BMP15 polyclonal antibody (Product # PA5-34401) at (A) 1 and (B) 2 µg/mL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of BMP15 in human testis tissue lysate with BMP-15 Polyclonal Antibody (Product # PA5-34401) at (A) 1 and (B) 2 µg/mL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of 3T3 cells using a BMP15 polyclonal antibody (Product # PA5-34401) at a 20 µg/mL dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry staining of 3T3 cells using a BMP15 polyclonal antibody (Product # PA5-34401) at a 25 µg/mL dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry of BMP15 in 3T3 cells with BMP-15 Polyclonal Antibody (Product # PA5-34401) at 2.5 µg/mL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry of BMP15 in 3T3 cells with BMP-15 Polyclonal Antibody (Product # PA5-34401) at 2.5 µg/mL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence of BMP15 in 3T3 cells with BMP-15 Polyclonal Antibody (Product # PA5-34401) at 20 µg/mL.

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 The effect of ASC/ASC-CM on the protein expression of GDF9 and BMP15 in oocytes shown by immunocytochemistry. ( a ) Immunocytochemical analysis of GDF9 (green) and BMP15 (green) in oocytes derived from three groups; control, ASC, and ASC-CM groups. ( b ) The fluorescence intensity for GDF9 and BMP15 in oocytes derived from three groups. Control: oocytes cultured without ASC or ASC-CM. ASC; oocytes cocultured with ASC during IVM. ASC-CM: oocytes cultured with ASC-derived conditioned medium during IVM. Data are shown as means +- SEM. a,b,c Within a column, values with different superscript letters are significantly different ( p < 0.05). At least six replications were performed. A total of 3 randomly selected oocytes derived from each group were used for a biological replication. GDF9; growth differentiation factor 9, BMP15; bone morphogenetic protein 15. The bar represents 50 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Evaluation of treatments with melatonin and brusatol on porcine COCs and their competences. With the treatment of 10 -9 M melatonin and 12 nM brusatol, their effects on the CC expansion and subsequent embryonic development were evaluated. The four experimental groups (control, melatonin, brusatol, and co-treatment) showed distinct differences in ( a , b ) the CC expansion, ( c ) cleavage rate, ( d ) blastocyst formation rate, and ( e ) total cell number. Additionally, protein expressions related to competence of the porcine COCs from each experimental group were evaluated by immunocytochemistry. The protein expression levels in ( f ) BMP15 and ( g ) GDF9 showed significant differences among the groups. Bars with letters indicate significant differences ( p < 0.05). 20x magnification, bars indicate 300 mum in Figure 2 a and 400x magnification, bars indicate 30 mum in Figure 2 f,g. At least three replicates were performed for each experiment.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Co-treatment of KP and LiCl during IVM and their effects on oocyte competence. ( A ) Expression levels of GDF9 and BMP15 in mature porcine oocytes. More than 20 oocytes from each group were used for the staining. X400 Magnification. ( B ) Treatment with KP significantly increased the competence of the oocytes, while treatment with LiCl decreased the competence. ( C ) Co-treatment of KP and LiCl. KP and LiCl had significant inverse effects on the cleavage rate and blastocyst formation rate compared to those observed in the control group, and the KP-treated group had the highest total number of blastocysts among all groups. A total of six replicates were performed. Bars with letters indicate significant differences ( P < 0.05).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Detection of BMP15 and GDF9 protein levels by immunofluorescence in porcine oocytes. ( A , B ) BMP15 expression in oocytes. ( C , D ) GDF9 expression in oocytes. Bars with different letters denote significant differences ( p < 0.05). Results are shown as the average +- SEM of at least three repeats of independent experiments.

PA5-34401